Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037201632> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2037201632 endingPage "473" @default.
- W2037201632 startingPage "468" @default.
- W2037201632 abstract "This phase II trial examined the efficacy and toxicity of first-line treatment with everolimus, paclitaxel, and carboplatin in patients with advanced melanoma. Seventy patients with metastatic or locally advanced unresectable melanoma who had been untreated previously with chemotherapy or targeted agents received first-line treatment with everolimus (5 mg, orally, daily), paclitaxel (175 mg/m2, intravenous, every 3 weeks), and carboplatin (area under the curve 6.0, intravenous, every 3 weeks). Response to treatment was assessed every 6 weeks; responding and stable patients received six cycles of paclitaxel and carboplatin, and subsequently continued single-agent everolimus until disease progression or unacceptable toxicity. Twelve patients (17%) showed objective responses (all partial); an additional 27 patients showed measurable tumor shrinkage. After a median follow-up of 15 months, the median progression-free survival was 4.0 months (95% confidence interval 2.8–5.0 months); the median survival for the entire group was 10.1 months. Myelosuppression was the most common grade 3/4 toxicity; 70% of patients experienced at least one episode of grade 3/4 toxicity while on study. Although this regimen was active in the first-line treatment of advanced melanoma, there was no suggestion of improved efficacy when compared with previous results with paclitaxel/carboplatin alone. Further study of this combination is not recommended." @default.
- W2037201632 created "2016-06-24" @default.
- W2037201632 creator A5004557221 @default.
- W2037201632 creator A5028976895 @default.
- W2037201632 creator A5035148529 @default.
- W2037201632 creator A5051120569 @default.
- W2037201632 creator A5065917441 @default.
- W2037201632 creator A5076017612 @default.
- W2037201632 date "2013-12-01" @default.
- W2037201632 modified "2023-09-27" @default.
- W2037201632 title "Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma" @default.
- W2037201632 cites W1981342298 @default.
- W2037201632 cites W2008793220 @default.
- W2037201632 cites W2016569614 @default.
- W2037201632 cites W2032870664 @default.
- W2037201632 cites W2060317877 @default.
- W2037201632 cites W2065701510 @default.
- W2037201632 cites W2089168156 @default.
- W2037201632 cites W2127120957 @default.
- W2037201632 cites W2167010784 @default.
- W2037201632 cites W2330814896 @default.
- W2037201632 cites W4293241248 @default.
- W2037201632 doi "https://doi.org/10.1097/cmr.0000000000000014" @default.
- W2037201632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23969699" @default.
- W2037201632 hasPublicationYear "2013" @default.
- W2037201632 type Work @default.
- W2037201632 sameAs 2037201632 @default.
- W2037201632 citedByCount "15" @default.
- W2037201632 countsByYear W20372016322015 @default.
- W2037201632 countsByYear W20372016322016 @default.
- W2037201632 countsByYear W20372016322017 @default.
- W2037201632 countsByYear W20372016322018 @default.
- W2037201632 countsByYear W20372016322019 @default.
- W2037201632 countsByYear W20372016322020 @default.
- W2037201632 countsByYear W20372016322022 @default.
- W2037201632 crossrefType "journal-article" @default.
- W2037201632 hasAuthorship W2037201632A5004557221 @default.
- W2037201632 hasAuthorship W2037201632A5028976895 @default.
- W2037201632 hasAuthorship W2037201632A5035148529 @default.
- W2037201632 hasAuthorship W2037201632A5051120569 @default.
- W2037201632 hasAuthorship W2037201632A5065917441 @default.
- W2037201632 hasAuthorship W2037201632A5076017612 @default.
- W2037201632 hasConcept C126322002 @default.
- W2037201632 hasConcept C126894567 @default.
- W2037201632 hasConcept C141071460 @default.
- W2037201632 hasConcept C143998085 @default.
- W2037201632 hasConcept C2776694085 @default.
- W2037201632 hasConcept C2777292972 @default.
- W2037201632 hasConcept C2778239845 @default.
- W2037201632 hasConcept C2779699572 @default.
- W2037201632 hasConcept C2781413609 @default.
- W2037201632 hasConcept C2781451048 @default.
- W2037201632 hasConcept C29730261 @default.
- W2037201632 hasConcept C71924100 @default.
- W2037201632 hasConceptScore W2037201632C126322002 @default.
- W2037201632 hasConceptScore W2037201632C126894567 @default.
- W2037201632 hasConceptScore W2037201632C141071460 @default.
- W2037201632 hasConceptScore W2037201632C143998085 @default.
- W2037201632 hasConceptScore W2037201632C2776694085 @default.
- W2037201632 hasConceptScore W2037201632C2777292972 @default.
- W2037201632 hasConceptScore W2037201632C2778239845 @default.
- W2037201632 hasConceptScore W2037201632C2779699572 @default.
- W2037201632 hasConceptScore W2037201632C2781413609 @default.
- W2037201632 hasConceptScore W2037201632C2781451048 @default.
- W2037201632 hasConceptScore W2037201632C29730261 @default.
- W2037201632 hasConceptScore W2037201632C71924100 @default.
- W2037201632 hasIssue "6" @default.
- W2037201632 hasLocation W20372016321 @default.
- W2037201632 hasLocation W20372016322 @default.
- W2037201632 hasOpenAccess W2037201632 @default.
- W2037201632 hasPrimaryLocation W20372016321 @default.
- W2037201632 hasRelatedWork W2012171803 @default.
- W2037201632 hasRelatedWork W2053778437 @default.
- W2037201632 hasRelatedWork W2120515886 @default.
- W2037201632 hasRelatedWork W2153557259 @default.
- W2037201632 hasRelatedWork W2289428780 @default.
- W2037201632 hasRelatedWork W2311734504 @default.
- W2037201632 hasRelatedWork W2387516978 @default.
- W2037201632 hasRelatedWork W2888392413 @default.
- W2037201632 hasRelatedWork W4238509468 @default.
- W2037201632 hasRelatedWork W4244943686 @default.
- W2037201632 hasVolume "23" @default.
- W2037201632 isParatext "false" @default.
- W2037201632 isRetracted "false" @default.
- W2037201632 magId "2037201632" @default.
- W2037201632 workType "article" @default.